GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Synageva BioPharma Corp's revenue per share for the three months ended in Mar. 2015 was $0.03. Synageva BioPharma Corp's revenue per share for the trailing twelve months (TTM) ended in Mar. 2015 was $0.18.
Synageva BioPharma Corp revenue has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Synageva BioPharma Corp was -47.10% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -34.40% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -51.30% per year. During the past 10 years, the average Revenue Per Share Growth Rate was -20.90% per year.
During the past 13 years, Synageva BioPharma Corp's highest 3-Year average Revenue Per Share Growth Rate was 158.00% per year. The lowest was -70.40% per year. And the median was 20.30% per year.
Revenue per Share is the amount of Revenue per outstanding share of the companys stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Synageva BioPharma Corp's Revenue Per Share for the fiscal year that ended in Dec. 2014 is calculated as
|Revenue Per Share (A: Dec. 2014 )||=||Revenue (A: Dec. 2014 )||/||Total Shares Outstanding (A: Dec. 2014 )|
Synageva BioPharma Corp's Revenue Per Share for the quarter that ended in Mar. 2015 is calculated as
|Revenue Per Share (Q: Mar. 2015 )||=||Revenue (Q: Mar. 2015 )||/||Total Shares Outstanding (Q: Mar. 2015 )|
Synageva BioPharma Corp Revenue Per Share for the trailing twelve months (TTM) ended in Mar. 2015 was 0.07 (Jun. 2014 ) + 0.04 (Sep. 2014 ) + 0.04 (Dec. 2014 ) + 0.03 (Mar. 2015 ) = $0.18
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth: Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Synageva BioPharma Corp Annual Data
|per share rev||2.42||3.46||11.18||4.41||3.40||18.59||0.71||0.66||0.48||0.20|
Synageva BioPharma Corp Quarterly Data
|per share rev||0.20||0.19||0.13||0.05||0.11||0.05||0.07||0.04||0.04||0.03|